Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting

Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting

Submitted by admin on October 17, 2022 - 11:17pm
Source: 
Fierce Biotech
News Tags: 
NCM Biopharmaceuticals
clinical trials
Merck
age-related macular degeneration
Headline: 
Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
snippet: 

As NGM Biopharmaceuticals’ phase 2 trial misses the mark, dreams for its Merck & Co.-partnered macular degeneration treatment may be disappearing from sight.

Do Not Allow Advertisers to Use My Personal information